Licensing partnership expanded across commercial healthcare
DataMeds AI expanded a licensing partnership with Datavault AI to use its data monetization and real-world asset tokenization technology across commercial healthcare.
The deal extends an earlier PharmacyChain-related license beyond pharmaceutical distribution into healthspan and wellness applications on the EinsteinRx platform.
Datavault AI is set to receive common shares equal to about 19.9% of DataMeds’ common stock at closing, replacing preferred shares.
The share issuance is contingent on closing related transactions, including acquisitions tied to QOLPOM IP portfolios and a controlling stake in Tollo Health.
DataMeds plans to use the technology for patient-controlled health data access and data-transaction models across pharmacy, medical, lab, and wearables settings.
MEDS•
